Amyvid (Florbetapir F-18) Patent Expiration, LOE Window & CMS Spending

Amyvid (Florbetapir F-18) by Avid Radiopharmaceuticals: FDA Orange Book core substance LOE 2027-04-30, 0 AB generics, $124K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAvid Radiopharmaceuticals
FDA Application & PathwayN202008 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-04-30
Last Listed Patent or Exclusivity Date2027-04-30
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$124K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$124K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel